Prognostic significance of hemoglobin levels in patients with primary epithelial ovarian carcinoma undergoing platinumbased chemotherapy

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 1, 2011, Pages 131-136

  Pongsanon, Khemmawan ^a   Benjapibal, Mongkol ^a   Ruengkhachorn, Irene ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Anemia; Ovarian cancer; Platinum based chemotherapy; Prognosis

Indexed keywords

EID: 79958742920     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Alici S, Kaya S, Izmirli M, et al. (2006). Analysis of survival factors in patients with advanced-stage gastric adenocarcinoma. Med Sci Monit, 12, CR221-9.
2. Ahlberg K, Ekman T, Gaston-Johansson F, et al. (2003). Assessment and management of cancer-related fatigue in adults. Lancet, 362, 40-50.
3. Albain KS, Crowley JJ, LeBlanc M, et al. (1991). Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol, 9, 1618-26.
4. Boogaerts M, Mittelman M, Vaupel P. (2005). Beyond anaemia management: evolving role of erythropoietin therapy in neurological disorders, multiple myeloma and tumour hypoxia models. Oncology, 69, 22-30.
5. Bron D, Meuleman N, Mascaux C. (2001). Biological basis of anemia. Semin Oncol, 28, 1-6.
6. Caro JJ, Salas M, Ward A, et al. (2001). Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer, 91, 2214-21.
7. Di Maio M, Pisano C, Tambaro R, et al. (2006). The prognostic role of pre-chemotherapy hemoglobin level in patients with ovarian cancer. Front Biosci, 11, 1585-90.
8. Dicato M. (2003). Anemia in cancer: some pathophysiological aspects. Oncologist, 8, 19-21.
9. Demetri GD, Kris M, Wade J, et al. (1998). Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit study group. J Clin Oncol, 16, 3412-25.
10. Eichbaum MH, Weiss LM, Bruckner T, et al. (2009). Prognostic impact of hemoglobin levels before and during carboplatin/ taxane-based chemotherapy in patients with primary invasive epithelial ovarian cancer. Med Sci Monit, 15, CR156-63.
11. Faquin WC, Schneider TJ, Goldberg MA. (1992). Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. lood, 79, 1987-94.
12. Gadducci A, Sartori E, Landoni F, et al. (2005). Pre-chemotherapy hemoglobin levels and survival in patients with advanced epithelial ovarian cancer who received a first-line taxane/ platinum-based regimen: results of a multicenter retrospective Italian study. Gynecol Oncol, 98, 18-23.
13. Glaspy J, Bukowski R, Steinberg D, et al. (1997). Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit study group. J Clin Oncol, 15, 1218-34.
14. Graeber TG, Osmanian C, Jacks T, et al. (1996). Hypoxiamediated selection of cells with diminished apoptotic potential in solid tumours. Nature, 379, 88-91.
15. Holzner B, Kemmler G, Greil R, et al. (2002). The impact of hemoglobin levels on fatigue and quality of life in cancer patients. Ann ncol, 13, 965-73.
16. Hockel M, Vaupel P. (2001). Biological consequences of tumor hypoxia. Semin Oncol, 28, 36-41.
17. Hockel M, Schlenger K, Aral B, et al. (1996). Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res, 56, 4509-15.
18. Ludwig H, Van Belle S, Barrett-Lee P, et al. (2004). The European cancer anaemia survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer, 40, 2293-306.
19. Liang BC. (1996). Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines. J Neurooncol, 29, 149-55.
20. Munstedt K, Kovacic M, Zygmunt M, et al. (2003). Impact of hemoglobin levels before and during chemotherapy on survival of patients with ovarian cancer. Int J Oncol, 23, 837-43.
21. MacRae R, Shyr Y, Johnson D, et al. (2002). Declining hemoglobin during chemoradiotherapy for locally advanced non-small cell lung cancer is significant. Radiother Oncol, 64, 37-40.
22. Memarzadeh S, Berek JS. (2001). Advances in the management of epithelial ovarian cancer. J Reprod Med, 46, 621-9.
23. Mercadante S, Gebbia V, Marrazzo A, et al. (2000). Anaemia inKhemmawan Pongsanon et al 136 Asian Pacific Journal of Cancer Prevention, Vol 12, 2011 cancer: pathophysiology and treatment. Cancer Treat Rev, 26, 303-11.
24. Obermair A, Petru E, Windbichler G, et al. (2000). Significance of pretreatment serum hemoglobin and survival in epithelial ovarian cancer. Oncol Rep, 7, 639-44.
25. Obermair A, Handisurya A, Kaider A, et al. (1998). The relationship of pretreatment serum hemoglobin level to the survival of epithelial ovarian carcinoma patients: a prospective review. Cancer, 83, 726-31.
26. Parkin DM, Bray F, Ferlay J, et al. (2005). Pisani P: Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108.
27. Reynolds TY, Rockwell S, Glazer PM. (1996). Genetic instability induced by the tumor microenvironment. Cancer Res, 56, 5754-7.
28. Stone P, Richardson A, Ream E, et al. (2000). Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Ann Oncol, 11, 971-5.
29. Tas F, Eralp Y, Basaran M, et al. (2002). Anemia in oncology practice: relation to diseases and their therapies. Am J Clin Oncol, 25, 71-9.
30. Thews O, Koenig R, Kelleher DK, et al. (1998). Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia. Br J Cancer, 78, 752-6.
31. Van Belle SJ and Cocquyt V. (2003). Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy. Crit Rev Oncol Hematol, 47, 1-11.
32. Vaupel P, Mayer A, Briest S, et al. (2003). Hockel M: Oxygenation gain factor: a novel parameter characterizing the association between hemoglobin level and the oxygenation status of breast cancers. Cancer Res, 63, 7634-7.
33. Vaupel P, Thews O, Hoeckel M. (2001). Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol, 18, 243-59.
34. Weiss G, Goodnough LT. (2005). Anemia of chronic disease. N Engl J Med, 352, 1011-23.
35. Young SD, Marshall RS, Hill RP. (1988). Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells. Proc Natl Acad Sci U S A, 85, 9533-7.